IL151172A0 - Amine derivatives, their preparation and use as bax modulators - Google Patents
Amine derivatives, their preparation and use as bax modulatorsInfo
- Publication number
- IL151172A0 IL151172A0 IL15117201A IL15117201A IL151172A0 IL 151172 A0 IL151172 A0 IL 151172A0 IL 15117201 A IL15117201 A IL 15117201A IL 15117201 A IL15117201 A IL 15117201A IL 151172 A0 IL151172 A0 IL 151172A0
- Authority
- IL
- Israel
- Prior art keywords
- amine derivatives
- preparation
- substituted amine
- modulators
- bax
- Prior art date
Links
- 150000001412 amines Chemical class 0.000 title abstract 4
- UJOBWOGCFQCDNV-UHFFFAOYSA-N Carbazole Natural products C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000004885 piperazines Chemical class 0.000 abstract 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- AIDS & HIV (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00810128A EP1125925A1 (en) | 2000-02-15 | 2000-02-15 | Amine derivatives for the treatment of apoptosis |
PCT/EP2001/001579 WO2001060798A1 (en) | 2000-02-15 | 2001-02-13 | Amine derivatives for the treatment of apoptosis |
Publications (1)
Publication Number | Publication Date |
---|---|
IL151172A0 true IL151172A0 (en) | 2003-04-10 |
Family
ID=8174551
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15117201A IL151172A0 (en) | 2000-02-15 | 2001-02-13 | Amine derivatives, their preparation and use as bax modulators |
IL151172A IL151172A (en) | 2000-02-15 | 2002-08-11 | Amine derivatives, their preparation and use as bax modulators |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL151172A IL151172A (en) | 2000-02-15 | 2002-08-11 | Amine derivatives, their preparation and use as bax modulators |
Country Status (12)
Country | Link |
---|---|
US (1) | US6770656B2 (xx) |
EP (2) | EP1125925A1 (xx) |
JP (1) | JP4875272B2 (xx) |
AT (1) | ATE383339T1 (xx) |
AU (1) | AU784086C (xx) |
CA (1) | CA2397651A1 (xx) |
DE (1) | DE60132309T2 (xx) |
DK (1) | DK1263730T3 (xx) |
ES (1) | ES2296747T3 (xx) |
IL (2) | IL151172A0 (xx) |
PT (1) | PT1263730E (xx) |
WO (1) | WO2001060798A1 (xx) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003074667A2 (en) * | 2002-03-01 | 2003-09-12 | Blood Center Research Foundation | Ku-70-derived bax-suppressing peptides and use thereof for the protection of damaged cells |
US7405234B2 (en) | 2002-05-17 | 2008-07-29 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
AU2003249713A1 (en) * | 2002-07-03 | 2004-01-23 | Axys Pharmaceuticals, Inc. | 3,4-dihydroisoquinolin-1-one derivatives as inducers of apoptosis |
AU2003302084A1 (en) * | 2002-11-15 | 2004-06-15 | Bristol-Myers Squibb Company | Open chain prolyl urea-related modulators of androgen receptor function |
US20080096824A1 (en) * | 2003-02-28 | 2008-04-24 | Shigemi Matsuyama | Ku-70-derived bax-suppressing peptides and use thereof for the protection of damaged cells |
US7820702B2 (en) | 2004-02-04 | 2010-10-26 | Bristol-Myers Squibb Company | Sulfonylpyrrolidine modulators of androgen receptor function and method |
US7625923B2 (en) | 2004-03-04 | 2009-12-01 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
US7696241B2 (en) | 2004-03-04 | 2010-04-13 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
TWI403320B (zh) | 2005-12-16 | 2013-08-01 | Infinity Discovery Inc | 用於抑制bcl蛋白和結合夥伴間之交互作用的化合物及方法 |
CN101959405B (zh) * | 2008-03-07 | 2014-07-02 | 转化技术制药有限责任公司 | 治疗糖尿病的氧杂二氮杂蒽化合物 |
JP5766614B2 (ja) | 2009-01-09 | 2015-08-19 | ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システムThe Board Of Regents Of The University Of Texas System | 神経新生促進化合物 |
US9962368B2 (en) | 2009-01-09 | 2018-05-08 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
US9162980B2 (en) | 2009-01-09 | 2015-10-20 | Board Of Regents Of The University Of Texas System | Anti-depression compounds |
US8362277B2 (en) | 2009-01-09 | 2013-01-29 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
US20110064806A1 (en) * | 2009-09-11 | 2011-03-17 | Transtech Pharma, Inc. | Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same |
WO2011106721A1 (en) * | 2010-02-26 | 2011-09-01 | The Regents Of The University Of Colorado, A Body Corporate | Flurbiprofen analogs and methods of use in treating cancer |
JP6126528B2 (ja) | 2010-07-07 | 2017-05-10 | ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システムThe Board Of Regents Of The University Of Texas System | 神経新生促進化合物 |
JP6033318B2 (ja) | 2011-10-14 | 2016-11-30 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 第XIa因子阻害剤としての置換テトラヒドロイソキノリン化合物 |
EP2899183B1 (en) | 2011-10-14 | 2018-09-19 | Bristol-Myers Squibb Company | Substituted Tetrahydroisoquinoline Compounds as Factor Xia Inhibitors |
ES2625256T3 (es) | 2011-10-14 | 2017-07-19 | Bristol-Myers Squibb Company | Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIA |
WO2014031986A1 (en) | 2012-08-24 | 2014-02-27 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
WO2014059202A1 (en) | 2012-10-12 | 2014-04-17 | Bristol-Myers Squibb Company | Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
WO2014059203A1 (en) | 2012-10-12 | 2014-04-17 | Bristol-Myers Squibb Company | Crystalline forms of a factor xia inhibitor |
US9403774B2 (en) | 2012-10-12 | 2016-08-02 | Bristol-Myers Squibb Company | Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
EP2978751B1 (en) | 2013-03-25 | 2018-12-05 | Bristol-Myers Squibb Company | Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors |
WO2015070234A2 (en) | 2013-11-11 | 2015-05-14 | Board Of Regents Of The University Of Texas System | Neuroprotective compounds and use thereof |
WO2015070237A1 (en) | 2013-11-11 | 2015-05-14 | Board Of Regents Of The University Of Texas System | Neuroprotective chemicals and methods for identifying and using same |
NO2760821T3 (xx) | 2014-01-31 | 2018-03-10 | ||
SG11201606209PA (en) | 2014-01-31 | 2016-08-30 | Bristol Myers Squibb Co | Macrocycles with hetrocyclic p2' groups as factor xia inhibitors |
JP6526796B2 (ja) | 2014-09-04 | 2019-06-05 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Fxia阻害剤であるジアミドマクロ環 |
US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
TWI790281B (zh) | 2017-09-13 | 2023-01-21 | 美商安進公司 | 雙醯胺肌節活化化合物及其用途 |
CA3142424A1 (en) * | 2019-05-31 | 2021-01-07 | Case Western Reserve University | Bax inhibitors and uses thereof |
WO2021211742A1 (en) * | 2020-04-14 | 2021-10-21 | The General Hospital Corporation | Use of gcn2 inhibitors in treating mitochondrial myopathies and diseases associated with mitochondrial dysfunction |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZW9580A1 (en) * | 1979-05-21 | 1981-12-23 | Ici Ltd | 1-phenyl-2-aminoethanol derivatives |
US5192773A (en) * | 1990-07-02 | 1993-03-09 | Vertex Pharmaceuticals, Inc. | Immunosuppressive compounds |
ATE183178T1 (de) * | 1991-05-09 | 1999-08-15 | Vertex Pharma | Neue immunsuppressive verbindungen |
FR2711990B1 (fr) * | 1993-11-05 | 1995-12-08 | Exsymol Sa | Produit pseudodipeptide possédant un groupement imidazole, et applications thérapeutiques, cosmétologiques et agroalimentaires. |
DE69535673D1 (de) | 1994-08-30 | 2008-02-07 | Univ Dundee | Mittel zur induktion von apoptosis und zur therapieanwendung |
AU731826B2 (en) * | 1996-02-28 | 2001-04-05 | Ariad Pharmaceuticals, Inc. | Synthetic Multimerizing Agents |
JP4473355B2 (ja) * | 1997-11-19 | 2010-06-02 | 武田薬品工業株式会社 | アポトーシス抑制剤 |
AR019322A1 (es) * | 1998-06-18 | 2002-02-13 | Smithkline Beecham Corp | Derivados de sulfonilo sustituido por heterociclo-etanodionanilina sustituida por heterociclo, composicion farmaceutica que los contiene y su uso para lamanufactura de un medicamento |
EP1094063A1 (en) * | 1999-10-18 | 2001-04-25 | Applied Research Systems ARS Holding N.V. | 9-(Piperazinylalkyl)carbazoles as Bax-modulators |
-
2000
- 2000-02-15 EP EP00810128A patent/EP1125925A1/en not_active Withdrawn
-
2001
- 2001-02-13 PT PT01927666T patent/PT1263730E/pt unknown
- 2001-02-13 DK DK01927666T patent/DK1263730T3/da active
- 2001-02-13 EP EP01927666A patent/EP1263730B1/en not_active Expired - Lifetime
- 2001-02-13 DE DE60132309T patent/DE60132309T2/de not_active Expired - Lifetime
- 2001-02-13 AT AT01927666T patent/ATE383339T1/de not_active IP Right Cessation
- 2001-02-13 JP JP2001560184A patent/JP4875272B2/ja not_active Expired - Fee Related
- 2001-02-13 ES ES01927666T patent/ES2296747T3/es not_active Expired - Lifetime
- 2001-02-13 WO PCT/EP2001/001579 patent/WO2001060798A1/en active IP Right Grant
- 2001-02-13 CA CA002397651A patent/CA2397651A1/en not_active Abandoned
- 2001-02-13 US US10/182,745 patent/US6770656B2/en not_active Expired - Fee Related
- 2001-02-13 IL IL15117201A patent/IL151172A0/xx active IP Right Grant
- 2001-02-13 AU AU54640/01A patent/AU784086C/en not_active Ceased
-
2002
- 2002-08-11 IL IL151172A patent/IL151172A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU5464001A (en) | 2001-08-27 |
ES2296747T3 (es) | 2008-05-01 |
ATE383339T1 (de) | 2008-01-15 |
JP4875272B2 (ja) | 2012-02-15 |
EP1263730A1 (en) | 2002-12-11 |
EP1125925A1 (en) | 2001-08-22 |
DE60132309T2 (de) | 2009-01-02 |
IL151172A (en) | 2008-04-13 |
US6770656B2 (en) | 2004-08-03 |
WO2001060798A1 (en) | 2001-08-23 |
AU784086B2 (en) | 2006-02-02 |
DK1263730T3 (da) | 2008-03-10 |
EP1263730B1 (en) | 2008-01-09 |
PT1263730E (pt) | 2008-02-11 |
JP2003523332A (ja) | 2003-08-05 |
CA2397651A1 (en) | 2001-08-23 |
DE60132309D1 (de) | 2008-02-21 |
AU784086C (en) | 2006-09-14 |
US20030216427A1 (en) | 2003-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL151172A0 (en) | Amine derivatives, their preparation and use as bax modulators | |
IL149163A0 (en) | Piperazine derivatives of carbazole, their preparation and pharmaceutical compositions containing them | |
IS6520A (is) | Ný efnasambönd | |
IS6658A (is) | Ný efnasambönd | |
ATE316083T1 (de) | Adamantanderivate | |
DK0889877T3 (da) | Meta-substituerede phenylenderivater og deres anvendelse som alfav-beta3-integrin-antagonister eller -inhibitorer | |
EA199900937A1 (ru) | Фармацевтические композиции, содержащие вориконазол | |
HUP0101999A2 (hu) | 4-Hidroxi-kinolin-3-karboxamid- és -hidrazid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása | |
BR0111263A (pt) | Derivados de 2-aminocarbonil-9h-purina | |
NO324217B1 (no) | Kondenserte azepinderivater og deres anvendelse som antidiuretiske midler | |
IL162498A (en) | Alpha-(n-sulphonamido) acetamide derivatives and pharmaceutical compositions containing the same | |
NO20025641D0 (no) | Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister | |
AU7517400A (en) | N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent | |
NO20025640D0 (no) | Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister | |
EP1193256A8 (en) | Pharmaceutically active benzsulfonamide derivatives as inhibitors of JNK proteins | |
PT992509E (pt) | Novos derivados macrolidos | |
SE0101038D0 (sv) | Novel compounds | |
DE60042831D1 (de) | Pharmazeutisch aktive sulfonylaminosäurederivate | |
MXPA04005313A (es) | Derivados de aminotetralin como antagonistas del receptor muscarinico. | |
DK0632026T3 (da) | Alfa-aminosyrederivater, en fremgangsmåde til deres fremstilling og farmaceutiske sammensætninger, der indeholder dem | |
DE69330601D1 (de) | Serotoninergische ergolin derivate | |
CA2374643A1 (en) | 1-trifluoromethyl-4-hydroxy-7-piperidinylaminomethylchroman derivatives as substance p antagonists | |
ZA200300218B (en) | Novel N-(2-phenyl-3-aminopropyl)naphtamides. | |
MXPA03010259A (es) | Nuevos derivados de 5-tio-ss-d-xilopiranosida, procedimiento de preparacion, composiciones farmaceuticas que los contienen y el uso terapeutico de los mismos. | |
SE0403117D0 (sv) | New compounds 1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed |